Range Impact (RNGE) 10-Q14 Feb 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
Document And Entity Information	Dec. 31, 2013	Feb. 13, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'Stevia First Corp.	'
Entity Central Index Key	'0001438943	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	66,432,523
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2014	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Dec. 31, 2013	Mar. 31, 2013
Current Assets	'	'
Cash	$1,831,189	$392,483
Security deposit	2,500	2,500
Prepaid expenses	9,306	9,073
Current portion of advance payment on related party lease	41,664	125,000
Total Current Assets	1,884,659	529,056
Advance payment on related party lease, net of current portion	0	10,417
Total Assets	1,884,659	539,473
Current Liabilities	'	'
Accounts payable and accrued liabilities	166,510	112,263
Accounts payable - Related Party	9,200	6,930
Accrued interest	0	9,375
Derivative liability	908,378	398,603
Total Current Liabilities	1,084,088	527,171
Total convertible notes	625,000	955,000
Less discount	-78,788	-374,592
Convertible notes payable, net of discount	546,212	580,408
Total liabilities	1,630,300	1,107,579
Stockholders' Equity (Deficit)	'	'
Common stock, par value $0.001 per share; 525,000,000 shares authorized; 65,587,012 and 55,659,102 shares issued and outstanding	65,587	55,659
Unvested, issued common stock	-165,471	-157,500
Additional paid-in-capital	7,254,302	3,707,772
Deficit accumulated during the development stage	-6,900,059	-4,174,037
Total stockholders' equity (deficit)	254,359	-568,106
Total liabilities and stockholders' equity (deficit)	$1,884,659	$539,473

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	525,000,000	525,000,000
Common stock, shares issued	65,587,012	55,659,102
Common stock, shares outstanding	65,587,012	55,659,102

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		78 Months Ended
CONDENSED STATEMENTS OF OPERATIONS (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenue	$0	$0	$0	$0	$0
Operating expenses:	'	'	'	'	'
General and administrative	796,017	499,275	2,120,541	1,475,111	5,169,759
Rent and other related party costs	42,150	41,150	115,250	107,600	283,500
Research and development	219,436	132,888	545,821	329,728	1,282,241
Total operating expenses	1,057,603	673,313	2,781,612	1,912,439	6,735,500
Loss from operations	-1,057,603	-673,313	-2,781,612	-1,912,439	-6,735,500
Other income (expenses)	'	'	'	'	'
Interest expense	-88,842	-69,468	-323,929	-122,421	-694,914
Change in fair value of derivative liability	275,232	234,321	553,343	234,321	678,197
Cost of Offering	0	-78,458	0	-78,458	-78,458
Cost to induce exercise of warrants	-173,824	'	-173,824	0	-173,824
Gain on settlement of debt	0	0	0	107,004	107,004
Foreign currency translation	0	160	0	-42	-2,564
Net loss	($1,045,037)	($586,758)	($2,726,022)	($1,772,035)	($6,900,059)
Loss per share - basic and diluted (in dollars per share)	($0.02)	($0.01)	($0.05)	($0.03)	'
Weighted average number of common shares outstanding- basic and diluted (in shares)	62,513,640	53,843,290	58,859,776	52,922,599	'

CONDENSED_STATEMENTS_OF_STOCKH

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Unvested Issued Common Stock [Member]	Deficit Accumulated During the Development Stage [Member]
Balance, amount at Mar. 31, 2013	($568,106)	$55,659	$3,707,772	($157,500)	($4,174,037)
Balance, shares at Mar. 31, 2013	'	55,659,102	'	'	'
Sale of common stock and warrants at $0.34 per unit, net of derivative value of warrants, value	-115,775	3,676	-119,451	0	0
Sale of common stock and warrants at $0.34 per unit, net of derivative value of warrants, shares	'	3,676,472	'	'	'
Common stock issued upon exercise of options, value	216,000	700	215,300	'	'
Common stock issued upon exercise of options, shares	700,000	700,000	'	'	'
Common stock issued upon exercise of warrants, value	1,824,505	4,677	1,819,828	'	'
Common stock issued upon exercise of warrants, shares	'	4,676,472	'	'	'
Common stock issued upon conversion of notes payable, value	330,000	733	329,267	0	0
Common stock issued upon conversion of notes payable, shares	'	733,334	'	'	'
Common stock issued to employees and director unvested, value	28,029	100	35,900	-7,971	0
Common stock issued to employees and director unvested, shares	'	100,000	'	'	'
Common stock issued as payment of accrued interest, value	37,500	42	37,458	0	0
Common stock issued as payment of accrued interest, shares	'	41,632	'	'	'
Cost to induce exercise of warrants	173,824	'	173,824	'	'
Extinguishment of derivative liabilities	185,907	'	185,907	'	'
Fair value of vested options	868,497	0	868,497	0	0
Net Loss	-2,726,022	0	0	0	-2,726,022
Balance, amount at Dec. 31, 2013	$254,359	$65,587	$7,254,302	($165,471)	($6,900,059)
Balance, shares at Dec. 31, 2013	'	65,587,012	'	'	'

CONDENSED_STATEMENTS_OF_STOCKH1

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) (USD $)	9 Months Ended
	Dec. 31, 2013
Per unit sale of common stock and warrants	$0.34

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		78 Months Ended
CONDENSED STATEMENTS OF CASH FLOWS (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Operating activities	'	'	'
Net loss	($2,726,022)	($1,772,035)	($6,900,059)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
expenses paid on behalf of the Company by third party	0	0	5,000
Stock based compensation	896,526	708,376	2,709,548
Gain on settlement of debt	0	-107,004	-107,004
Cost of Offering	0	78,458	78,458
Cost to induce exercise	173,824	0	173,824
Change in fair value of derivative liability	-553,343	-234,321	-678,197
Amortization of debt discount	295,804	86,018	598,616
Cancellation of fees applied to option exercise price	0	0	0
Prepaid expenses	-233	-24,961	-9,306
Advance payment on related party lease	93,753	-166,666	-41,664
Accrued interest	28,125	24,328	84,208
Accounts payable - related party	2,270	-1,330	9,200
Accounts payable and accrued liabilities	194,247	143,894	497,510
Net cash used in operating activities	-1,595,049	-1,265,243	-3,579,866
Financing activities	'	'	'
Proceeds from issuance of promissory notes	0	'	196,800
Proceeds from issuance of convertible notes, net	0	870,000	1,320,000
Proceeds from exercise of options	76,000	35,000	289,000
Proceeds from exercise of warrants, net	1,824,505	0	1,824,505
Proceeds from sale of common stock, net	1,133,250	425,000	1,783,250
Net cash provided by financing activities	3,033,755	1,330,000	5,413,555
Investing activities	'	'	'
Security deposit	0	-1,000	-2,500
Net cash used in investing activities	0	-1,000	-2,500
Net increase in cash	1,438,706	63,757	1,831,189
Cash and cash equivalent - beginning of period	392,483	532,206	0
Cash and cash equivalent - end of period	1,831,189	595,963	1,831,189
Cash paid during the period for:	'	'	'
Interest	0	12,075	12,075
Income taxes	0	0	0
Non-cash activities:	'	'	'
Fair value of warrants issued with common stock recorded as derivative liability	1,249,025	0	1,249,025
Cancellation of accounts payable applied to option exercise price	140,000	140,000	336,000
Issuance of common stock upon conversion of convertible and promissory notes payable and accrued interest	367,500	133,254	924,004
Fair value of beneficial conversion feature of convertible notes	0	0	177,404
Fair value of warrants issued with convertible debentures, recognized as a note discount	0	500,000	500,000
Loan (expenses paid on behalf of Company by third party)	0	0	-5,000
Extinguishment of warrant derivative	$185,907	$0	$185,907

BUSINESS_AND_BASIS_OF_OPERATIO

BUSINESS AND BASIS OF OPERATIONS	9 Months Ended
BUSINESS AND BASIS OF OPERATIONS	Dec. 31, 2013
Nature and Continuance Of Operation [Abstract]	'
BUSINESS AND BASIS OF OPERATIONS	'
	1. BUSINESS AND BASIS OF OPERATIONS

	Stevia First Corp. (the “Company”, “we”, “us” or “our”), was incorporated under the laws of the State of Nevada on June 29, 2007 under the name Legend Mining Inc. During the period from July 1, 2007 (inception) to June 30, 2011, the Company commenced operations by issuing shares and acquiring a mineral property located in the Province of Saskatchewan, Canada. The Company was unable to keep the mineral claim in good standing due to lack of funding, and accordingly its interest in it has expired. On October 10, 2011, the Company completed a merger with its wholly-owned subsidiary, Stevia First Corp., whereby it changed its name to “Stevia First Corp.” In connection with a related change in management, the addition of key personnel, and the lease of property for laboratory and office space in California, the Company is now pursuing its new business as an agricultural biotechnology company engaged in the cultivation and harvest of stevia leaf and the development of stevia products. The Company has not produced any revenues and is considered a development stage company. The Company's fiscal year end is March 31.

	Liquidity

	These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception resulting in an accumulated deficit of $6,900,059 as at December 31, 2013, and further losses are anticipated in the development of its business. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. As a result, the Company’s independent registered public accounting firm, in their report on the Company’s March 31, 2013 financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

	The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. After giving effect to the funds received in recent equity and debt financings, we estimate as of December 31, 2013 we will have sufficient funds to operate the business for the next 12 months. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, seeking to license or acquire new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect.

	We do not have any firm commitments for future capital. Significant additional financing will be required to fund our planned operations in the near term and in future periods, including research and development activities relating to stevia extract production, developing and seeking regulatory approval for any of our stevia product candidates, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We do not presently have, nor do we expect in the near future to have, revenue to fund our business from our operations, and will need to obtain all of our necessary funding from external sources in the near term. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to develop our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

	Basis of Presentation of Unaudited Condensed Financial Information

	The unaudited condensed financial statements of the Company for the three and nine months ended December 31, 2013 and 2012 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of March 31, 2013 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended March 31, 2013 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on May 20, 2013. These financial statements should be read in conjunction with that report.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Development Stage Company

The Company is a development stage enterprise pursuant to applicable guidance of the Financial Accounting Standards Board (“FASB”), and is devoting substantially all of its present efforts to establishing its business and has not produced any revenues from its operations .

Use of Estimates and Assumptions

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of shares issued for services, fair value of warrants issued in conjunction with convertible debentures, and assumptions used in the valuation of conversion features and derivative liabilities.

Financial Assets and Liabilities Measured at Fair Value

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the condensed balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by the FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets:

Level 1

Quoted prices in active markets for identical assets or liabilities.

Level 2

Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3

Unobservable inputs based on the Company’s assumptions.

The following table presents certain investments and liabilities of the Company’s financial assets measured and recorded at fair value on the Company’s condensed balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2013 and March 31, 2013:

31-Dec-13

Level 1

Level 2

Level 3

Total

Fair value of Derivative Liability

908,378

31-Mar-13

Level 1

Level 2

Level 3

Total

Fair value of Derivative Liability

398,603

The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the December 31, 2013 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Income Taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.

Stock-Based Compensation

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.

Basic and Diluted Loss Per Share

The Company computes loss per share in accordance with ASC Topic 260, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the three and nine months ended December 31, 2013 and 2012, the calculations of basic and diluted loss per share are the same because inclusion of potential dilutive securities in the computation would have an anti-dilutive effect due to the net losses.

The potentially dilutive securities at December 31, 2013 consist of options to acquire 4,975,000 shares of the Company’s common stock, warrants to acquire 7,727,129 shares of common stock, and 693,773 shares of common stock potentially issuable under convertible note agreements.

Recent Accounting Pronouncements

In March 2013, the FASB issued Accounting Standards Update (“ASU”) 2013-05 (Topic 830), “Foreign Currency Matters” (“ASU 2013-05”). ASU 2013-05 resolves the diversity in practice about whether Subtopic 810-10, Consolidation—Overall, or Subtopic 830-30, ASU 2013-05, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. ASU 2013-05 became effective for the company prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material effect on the Company’s financial statements.

The FASB has issued ASU No. 2013-04, Liabilities (Topic 405), “Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date” (“ASU 2013-04”). ASU 2013-04 provides guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this ASU is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not expect the adoption of this guidance to have a material impact on the Company’s financial statements.

In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740) “Presentation of Unrecognized Tax Benefit When a Net Operating Loss Carryforward, A Similar Tax Loss, or a Tax Credit Carryforward Exists (A Consensus the FASB Emerging Issues Task Force)” (“ASU 2013-11”) . ASU 2013-11 provides guidance on financial statement presentation of unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The FASB’s objective in issuing this ASU is to eliminate diversity in practice resulting from a lack of guidance on this topic in current U.S. GAAP. This ASU applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date. This update is effective for public entities for fiscal years beginning after December 15, 2013 and interim periods within those years. The Company does not expect the adoption of this standard to have a material impact on the Company’s financial statements.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA, and the Securities and Exchange Commission (“SEC”) did not or are not believed by management to have a material impact on the Company's present or future financial statements.

Reclassification

In presenting the Company’s statement of operations for the three and nine months ended December 31, 2012, the Company previously presented $91,231 and $198,981, respectively, as general and administrative expenses. In presenting the Company’s statement of operations for the three and nine months ended December 31, 2013, the Company has reclassified these expenses to research and development.

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	9 Months Ended
	Dec. 31, 2013
Convertible Note Payable [Abstract]	'
CONVERTIBLE NOTES PAYABLE	'
	3. CONVERTIBLE NOTES PAYABLE

	Convertible notes payable consist of the following as of December 31, 2013 and March 31, 2013:

		December 31,		March 31,
		2013		2013
	Subordinated unsecured convertible notes payable, interest at 6% per	$	625,000	$	625,000
	annum payable semi-annually (a)
	Convertible notes payable (b)		-		330,000
	Total convertible notes		625,000		955,000

	Less: note discount		-78,788		-374,592
	Convertible notes payable, net of note discount	$	546,212	$	580,408

	(a) On February 7, 2012, the Company entered into a Subscription Agreement (the “Subscription Agreement”) with one investor in a private placement, pursuant to which such investor purchased an aggregate of (i) 625,000 shares of common stock at a purchase price of $1.00 per share and (ii) convertible debentures with an aggregate principal amount of $ 625,000 convertible into a total of 693,774 shares of our common stock at prices ranging from $0.65 to $1.25, in five tranches over a 12 month period beginning on March 1, 2012, for proceeds to us of $ 250,000 per tranche. The conversion price of the common stock underlying each of the convertible debentures is subject to adjustment upon a reclassification or other change in the Company’s outstanding common stock and certain distributions to all holders of the Company’s common stock. The entire principal balance of each debenture is due and payable three years following its date of issuance unless earlier redeemed by the Company in accordance with its terms. Each of these convertible debentures bears interest at the rate of 6.0 % per annum, payable semi-annually in arrears on June 30 and December 31 of each year. During the nine months ended December 31, 2013, the aggregate accrued interest due on these convertible debentures of $37,500 was converted into 41,632 shares of the Company’s common stock based on the conversion rates of the five tranches of these convertible debentures ranging from $0.65 to $1.25 per share. As of December 31, 2013, all $625,000 of these convertible debentures were outstanding. If the outstanding principal on all of the convertible debentures issued pursuant to the Subscription Agreement were converted into common shares, as of December 31, 2013, the holders thereof would receive 693,773 shares of common stock.

	Upon the issuance of the convertible notes under the Subscription Agreement, the market price of our common shares was in excess of the conversion price, creating a beneficial conversion feature of $177,404 upon issuance, representing the amount by which the value of the shares into which the notes are convertible exceeded the aggregate conversion price on the date of issuance. The beneficial conversion feature was recorded as a discount to the notes payable and is being amortized over the life of the notes, the balance of which was $113,341 at March 31, 2013. During the nine months ended December 31, 2013, the Company recognized interest expense of $34,553 relating to the amortization of this discount, resulting in an unamortized balance of $78,788 as of December 31, 2013.

	(b) On October 29, 2012, we entered into a Securities Purchase Agreement with two investors providing for the issuance and sale of an aggregate of $500,000 in convertible debentures and warrants to purchase 1,000,000 shares of our common stock, for proceeds to us of $500,000. The financing closed on November 1, 2012. After deducting for fees and expenses, the aggregate net proceeds from the sale of the debentures and warrants was $445,000. During the year ended March 31, 2013, $170,000 of these debentures were converted into shares of the Company’s common stock leaving a balance due on these debentures at March 31, 2013 of $330,000. During the nine months ended December 31, 2013, the remaining debentures, totaling $330,000, were converted into 733,334 shares of common stock. As of December 31, 2013, there was no remaining balance due on these debentures and they have been cancelled in full.

	Each of the investors was also issued a warrant to purchase up to a number of shares of the Company’s common stock equal to 100% of the shares initially issuable to such investor upon conversion of the convertible debentures issued pursuant to the Securities Purchase Agreement, totaling up to 1,000,000 shares of common stock. The warrants had an initial exercise price of $0.70 per share, are exercisable immediately upon issuance and have a term of exercise equal to five years. The Company also issued warrants to purchase up to 80,000 shares of the Company’s common stock to its placement agent related to the financing that had an initial exercise price of $0.625 per share. On March 6, 2013, the exercise price of all the warrants was reduced to $0.50. On June 28, 2013, the exercise price of all of the warrants issued in the October 2012 financing was further reduced to $0.34.

	Each of the warrants includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants issued with the convertible debentures, provided that the exercise price shall not be reduced to less than $0.20 per share. The Company considered the current FASB guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” and determined that the exercise price of the warrants is not a fixed amount because it is subject to fluctuation based on the occurrence of future offerings or events. As a result, the Company determined that the warrants are not considered indexed to the Company’s own stock and characterized the initial fair value of these warrants as a derivative liability upon issuance. The Company determined the aggregate initial fair value of the warrants issued to investors and placement agent to be $523,458 upon issuance. These amounts were determined by management using a using a probability weighted average Black-Scholes Merton option pricing model.

	The total cost to the Company of the transactions related to the Securities Purchase Agreement was $578,458, which includes placement fees and expenses of $55,000 and the fair value of the warrant derivative of $523,458. To account for the these costs, the Company recorded a valuation discount of $500,000 upon issuance, and the incremental cost of $78,458 over the face amount of the convertible debentures was recorded as a financing cost during the year ended March 31, 2013. The Company was amortizing the valuation discount to interest expense over the life of the convertible debentures. During the nine months ended December 31, 2013, the Company recognized interest expense of $261,251 relating to the amortization of this discount, resulting in an unamortized balance of $0 as of December 31, 2013.

DERIVATIVE_LIABILITY

DERIVATIVE LIABILITY	9 Months Ended
DERIVATIVE LIABILITY	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
DERIVATIVE LIABILITY	'
	4. DERIVATIVE LIABILITY

	In June 2008, the FASB issued authoritative guidance on determining whether an instrument (or embedded feature) is indexed to an entity’s own stock. Under the authoritative guidance, effective January 1, 2009, instruments which do not have fixed settlement provisions are deemed to be derivative instruments. The warrants issued to investors and placement agents in relation to the securities purchase agreements described in Notes 3 and 5 do not have fixed settlement provisions because their exercise prices will be lowered if the Company issues securities at lower prices in the future. The Company was required to include the reset provisions in order to protect the holders of the warrants from the potential dilution associated with future financings. In accordance with the FASB authoritative guidance, the warrants issued pursuant to the securities purchase agreements have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.

	At December 31, 2013, and as of March 31, 2013, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions:

	Warrants:

		December 31,			At Date of			March 31,
		2013			Issuance			2013
	Exercise Price	$	0.34-0.425		$	0.40 - $0.60		$	0.5
	Stock Price	$	0.42		$	0.35		$	0.45

	Risk-free interest rate		.02-1.295	%		2.52	%		0.25	%
	Expected volatility		46.94	%		78.7	%		123.68	%
	Expected life (in years)		0.25-4.5 years			0.50 - 5.0 years			4.5 years
	Expected dividend yield		0			0			0
	Fair Value:	$	908,378		$	1,249,025		$	398,603

	The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.

	At March 31, 2013, the fair value of the derivative liability of the warrants issued in conjunction with the convertible notes, as described in Note 3, was $398,603. During the nine months ended December 31, 2013, we recognized an additional derivative liability of $1,249,025 related to the issuance of additional warrants upon the sale of common stock on June 28, 2013, as described in Note 5. During the three months ended December 31, 2013, the Company extinguished a portion of the derivative liability, with a fair value of 185,907, pursuant to the exercise of certain of the warrants, as described in Note 7. As of December 31, 2013 the derivative liability of all outstanding warrants was $908,378. For the nine months ended December 31, 2013, the Company recorded a change in fair value of the derivative liability of $553,343.

EQUITY

EQUITY	9 Months Ended
EQUITY	Dec. 31, 2013
E Q U I T Y [Abstract]	'
EQUITY	'
	5. EQUITY

	Equity financing

	On June 25, 2013, the Company entered into a Securities Purchase Agreement with three investors for the sale of an aggregate of 3,676,472 shares of the Company's common stock and warrants to purchase an aggregate of 11,029,416 shares of the Company’s common stock for total gross proceeds of $1,250,000, or a sales price of $0.34 per share. The offering closed on June 28, 2013. The Company incurred $116,750 of direct costs in connection with the financing, resulting in net cash proceeds to the Company of $1,133,250. The purchasers who entered into the Securities Purchase Agreement were also issued warrants to purchase up to 11,029,416 shares of the Company’s common stock. The warrants were issued in three series of 3,676,472 each and have initial exercise prices of $0.40, $0.50 and $0.60 per share, respectively, are exercisable immediately upon issuance and have a term of exercise equal to five years, six months and nine months, respectively. The Company also issued warrants to purchase up to 294,185 shares of the Company’s common stock to its placement agent related to the financing. The placement agent’s warrants have an exercise price of $0.425 per share and a term of five years and are exercisable immediately.

	Each of the warrants includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants issued with the convertible debentures, provided that the exercise price shall not be reduced to less than $0.20 per share. The Company considered the current FASB guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” and determined that exercise price of the warrants are not a fixed amount because they are subject to fluctuation based on the occurrence of future offerings or events. As a result, the Company determined that the warrants are not considered indexed to the Company’s own stock and characterized the initial fair value of these warrants as derivative liabilities upon issuance. The Company determined the aggregate initial fair value of the warrants issued to investors and the placement agent in the financing to be $1,249,025 at issuance based upon a weighted average Black-Scholes option pricing model. For financial statement purposes, the amount of the derivative liability created from the issuance of the warrants of $1,249,025 has been offset to the net cash proceeds received of $1,133,250, resulting in a net reduction of additional paid in capital of $115,775 resulting from the sale of the shares and warrants.

	Common stock issued to employees

	In July and August 2012, the Company issued an aggregate of 700,000 shares of its common stock to employees and a director of the Company vesting over a period ranging from 16 months to 60 months from the date of grant under the Company's stock option and incentive plan (the “2012 Stock Incentive Plan”). These shares of common stock issued to employees and a director were valued based upon the market price of the Company’s common stock at the dates of grant for an aggregate fair value of $189,000. As the shares were issued, but not yet vested, the aggregate fair value of these shares was accounted for as a contra-equity account that is being amortized over the vesting term of the common stock award. During the nine months ended December 31, 2013, the Company amortized $80,604 of the fair value of the common stock as services were provided and recognized as stock compensation in the Company’ s statement of operations, and $76,896 remained unamortized as of the period then ended.

	In July 2013, the Company issued 100,000 shares of its common stock to an employee of the Company vesting over a period of 31 months from the date of grant under the Company's 2012 Stock Incentive Plan. These shares of common stock issued to employee were valued based upon the market price of the Company’s common stock at the date of grant for an aggregate fair value of $36,000. As the shares were issued, but not yet vested, the aggregate fair value of these shares was accounted for as a contra-equity account that is being amortized over the vesting term of the common stock award. During the nine months ended December 31, 2013, the Company amortized $6,968 of the fair value of the common stock as services were provided and recognized as stock compensation in the Company’ s statement of operations, and $28,029 remained unamortized as of the period then ended.

STOCK_OPTIONS

STOCK OPTIONS	9 Months Ended
STOCK OPTIONS	Dec. 31, 2013
Stock Options [Abstract]	'
STOCK OPTIONS	'
	6. STOCK OPTIONS

	Pursuant to the terms of the 2012 Stock Incentive Plan, the exercise price for all equity awards issued under the 2012 Stock Incentive Plan is based on the market price per share of the Company’s common stock on the date of grant of the applicable award.

	A summary of the Company’s stock option activity under the 2012 Stock Incentive Plan for the period ended December 31, 2013 is presented below:

		Shares	Weighted
			Average
			Exercise
			Price
	Balance at March 31, 2013	2,275,000	$	0.16
	Granted	3,500,000		0.39
	Exercised	-700,000		0.31
	Cancelled	-100,000		0.42
	Balance outstanding at December 31, 2013	4,975,000	$	0.27
	Balance exercisable at December 31, 2013	3,620,833	$	0.26

	At December 31, 2013, options to purchase common shares were outstanding as follows:

		Number of	Weighted		Weighted
		options	Average		Average
			Exercise		Grant-date Stock
			Price		Price

	Options Outstanding, December 31, 2013	1,650,000	$	0.1	$	1
		200,000	$	0.27	$	0.27
		1,000,000	$	0.32	$	0.32
		300,000	$	0.35	$	0.35
		100,000	$	0.36	$	0.36
		1,600,000	$	0.4	$	0.4
		25,000	$	0.42	$	0.42
		100,000	$	0.44	$	0.44

		4,975,000

	Exercisable, December 31, 2013	1,362,500	$	0.1	$	1
		83,333	$	0.27	$	0.27
		500,000	$	0.32	$	0.32
		75,000	$	0.35	$	0.35
		1,600,000	$	0.4	$	0.4
		3,620,833

	During the nine months ended December 31, 2013, the Company granted 500,000 options to consultants and an employee that expire ten years after the date of grant , 100,000 of which vested immediately and 400,000 of which have a vesting period ranging from four months to twelve months. In addition, the Company granted 3,000,000 options to consultants that expire three years after the date of grant , 2,000,000 of which vested immediately and 1,000,000 of which vest two months from the grant date. All such options were issued under the 2012 Stock Incentive Plan. Assumptions used in valuing stock options granted during the nine months ended December 31, 2013 are as follows: (i) volatility rate of between 46.94% and 78.7%, (ii) discount rate of between 0.25% and 0.63%, (iii) zero expected dividend yield, and (iv) expected life of 3 or 10 years for options granted to consultants based upon the contractual term of the options and an expected life of approximately 5 years for options granted to employees. For employees the expected life is the average of the term of the option and the vesting period. The aggregate fair value of the options granted during the nine months ended December 31, 2013 was approximately $760,000.

	During the nine months ended December 31, 2013 and 2012, we expensed total stock-based compensation related to vesting stock options of $868,497 and $708,376, respectively, and the remaining unamortized cost of the outstanding stock-based awards at December 31, 2013 was $136,189. This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years and will be adjusted for subsequent changes in estimated forfeitures. Future option grants will increase the amount of compensation expense that will be recorded.

	The aggregate intrinsic value of all outstanding stock options at December 31, 2013, was $755,000.

WARRANTS

WARRANTS	9 Months Ended
	Dec. 31, 2013
Warrants [Abstract]	'
WARRANTS	'
	7. WARRANTS

	At December 31, 2013, warrants to purchase common shares were outstanding as follows:

		Shares	Weighted
			Average
			Exercise
			Price
	Balance at March 31, 2013	1,080,000	$	0.5
	Granted	11,323,601		0.5
	Exercised	-4,676,472		0.41
	Cancelled	-	$	-
	Balance outstanding at December 31, 2013	7,727,129	$	0.41
	Balance exercisable at December 31, 2013	7,727,129

	The purchasers who entered into the Securities Purchase Agreement on October 29, 2012, described in Note 3, were issued warrants to purchase up to 1,000,000 shares of the Company’s common stock. The warrants had an initial exercise price of $0.70 per share, were exercisable immediately upon issuance and had a term of exercise equal to five years. On March 6, 2013, the exercise price of the warrants was reduced to $0.50, and on June 28, 2013, the exercise price was further reduced to $0.34 per share. We also issued warrants to purchase up to 80,000 shares of the Company’s common stock to the placement agent in the offering. The placement agent’s warrants had an initial exercise price of $0.625 per share and a term of five years and are exercisable immediately. The exercise price of the placement agent warrants was reset to $0.50 on March 6, 2013. On June 28, 2013, the exercise price of the placement agent’s warrants was reduced to $0.34. During the current period ended December 31, 2013, the purchasers exercised all of their warrants and acquired 1,000,000 shares of the Company’s common stock at the then-effective exercise price of $0.34 per share, resulting in $340,000 in proceeds to the Company. All of the placement agent’s warrants remained outstanding as of December 31, 2013.

	The purchasers who entered into the Securities Purchase Agreement on June 25, 2013, described in Note 5, were issued warrants to purchase up to 11,029,416 shares of the Company’s common stock. The warrants were issued in three series of 3,676,472 each and had initial exercise prices of $0.40, $0.50 and $0.60 per share, respectively, are exercisable immediately upon issuance, and have a term of exercise equal to five years, six months and nine months, respectively. The Company also issued warrants to purchase up to 294,185 shares of the Company’s common stock to its placement agent in the financing. The placement agent warrants have an exercise price of $0.425 per share and a term of five years and are exercisable immediately.

	In November and December 2013, certain purchasers exercised some of their six-month warrants and acquired an aggregate of 314,000 shares of the Company's common stock at the then-effective exercise price of $0.50 per share, resulting in proceeds of $157,000 to the Company. On December 6, 2013, the Company offered the purchasers holding the remaining six-month warrants the right to exercise all of those warrants, for an aggregate of 3,362,472 shares of the Company’s common stock, based on the terms of an early exercise offer wherein such warrants became exercisable at a reduced exercise price of $0.42 per share, so long as the exercise thereof occurred on or before December 9, 2013. All purchasers acted on the early exercise offer and the Company issued 3,362,472 shares of its common stock, resulting in proceeds of $1,327,504 to the Company. The Company determined that the modification of the exercise price of the warrants from $0.50 per share to $0.42 per share should be recorded as a cost to induce the exercise of the warrants. As such, the Company recognized the difference of $173,824 between the fair value of the warrants before and after the modification as a cost in the accompanying statement of operations for the nine months ended December 31, 2013.

	In consideration of applicable guidance, the Company has determined that none of the warrants are considered indexed to the Company’s own stock, since the exercise prices of the warrants are subject to fluctuation based on the occurrence of future offerings or events and are not a fixed amount, and therefore characterizes the fair value of these warrants as derivative liabilities (See Note 4). The aggregate intrinsic value of all of the outstanding warrants at December 31, 2013 was $78,459.

INCOME_TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	8. INCOME TAXES

	The Company has no tax provision for any period presented due to our history of operating losses. As of December 31, 2013, the Company had net operating loss carry forwards of approximately $6,900,059 that may be available to reduce future years' taxable income through 2029. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as management has determined that their realization is not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

RELATED_PARTY_TRANSACTIONS_AND

RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	9 Months Ended
RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	Dec. 31, 2013
Related Party Transactions and Lease Obligations Disclosure [Abstract]	'
RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS	'
	9. RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS

	Advance payment of related party lease

	On April 23, 2012, the Company entered into a lease agreement (the “Sutter Lease”) with Sutter Buttes LLC (“Sutter Buttes”), pursuant to which the Company has agreed to lease from Sutter Buttes approximately 1,000 acres of land in Sutter County, California on which the Company may either cultivate and harvest the stevia plant or locate stevia processing facilities. The Sutter Lease begins on May 1, 2012 and expires on May 1, 2014 and the Company has paid the aggregate amount of all rent payments thereunder, totaling $250,000. Sutter Buttes, the landlord under the Sutter Lease, is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains.

	The amount of all rent payments under the Sutter Lease of $250,000 was accounted for by the Company as an asset, Advance payment of related party lease, and is being amortized over the term of the lease of 24 months. During the nine months ended December 31, 2013, the Company recognized rent expense of $93,750 related to the Sutter Lease. As of December 31, 2013, the unamortized advance payment of the related party lease was $41,664.

	Other related party lease obligations

	Effective as of September 1, 2011, the Company entered into an unsecured lease agreement with One World Ranches LLC (“One World Ranches”), which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, for office and laboratory space located at 5225 Carlson Rd., Yuba City, CA 95993 for a term of five years expiring on September 1, 2016 at a rate of $1,000 per month. Effective as of January 1, 2012, the Company modified the lease agreement to provide for additional office and laboratory space for an additional $500 per month, for a total rental payment of $1,500 per month.

	On April 23, 2012, the Company entered into a further lease agreement with One World Ranches, pursuant to which the Company has agreed to lease from One World Ranches certain office and laboratory space located at 5225 Carlson Road, Yuba City, California, which supersedes and replaces the prior lease (such current lease agreement, the “Carlson Lease”). The Carlson Lease began on May 1, 2012 and expires on May 1, 2017, and the Company’s rent payments thereunder are $2,300 per month. The Company has paid $1,500 as a refundable security deposit under the Carlson Lease.

	On August 18, 2012, the Company entered into a lease agreement (the “Sacramento Lease”) with Sacramento Valley Real Estate, pursuant to which the Company leases an apartment, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, located at 33-800 Clark Avenue, Yuba City, California. This Company uses this apartment as an alternative to renting hotel rooms for management use since several of our managers are not resident in Yuba City. The month to month lease began on August 20, 2012 and the Company’s rent payment is $1,000 per month. On August 22, 2012, the Company paid $1,000 as a refundable security deposit under the Sacramento lease.

	Aggregate payments under the above leases for the nine months ended December 31, 2013 and 2012 were $115,250 and $107,600, respectively.

COMMITMENTS

COMMITMENTS	9 Months Ended
COMMITMENTS	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
COMMITMENTS	'
	10. COMMITMENTS

	We have exclusive and worldwide rights to patents and patent applications obtained through a license agreement with Vineland Research and Innovations Centre, Inc. entered into in August 2012 and amended in October 2013 (the “Vineland License”). The patent family includes an issued U.S. patent, an issued European Union patent, and an issued Canadian patent. The patents and patent applications relate to microbial production of steviol and steviol glycosides. The Vineland License has an initial term of 10 years and may be renewed by us for additional two-year terms until all licensed patents have expired. Pursuant to the Vineland License, we agreed to total cash fees due and payable within the first year of $50,000, all of which has been paid and recorded as expenses. In addition to these cash fees, we will owe royalties of 0.5% of the sale price of products developed using the intellectual property, and in the third year and all subsequent years of the Vineland License the Company will owe a minimum annual royalty of $10,000. On October 10, 2013, we entered into an amendment to the Vineland License, pursuant to which Vineland agreed to license to us an additional patent application and to pay up to $50,000 in patent prosecution cost related to the new patent application.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	11. SUBSEQUENT EVENTS

	One holder exercised options to purchase 150,000 shares of the Company’s common stock in January 2014 at an exercise price of $0.10 per share. The Company received proceeds of $15,000 from this exercise.

	In February 2014, convertible debentures in the amount of $625,000 and accrued interest of $1,562.50 were converted into a total of 695,511 shares of the Company’s common stock.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Development Stage Company

Use of Estimates and Assumptions

Financial Assets and Liabilities Measured at Fair Value

Level 1

Quoted prices in active markets for identical assets or liabilities.

Level 2

Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3

Unobservable inputs based on the Company’s assumptions.

31-Dec-13

Level 1

Level 2

Level 3

Total

Fair value of Derivative Liability

908,378

31-Mar-13

Level 1

Level 2

Level 3

Total

Fair value of Derivative Liability

398,603

Derivative Financial Instruments

Income Taxes

Stock-Based Compensation

Basic and Diluted Loss Per Share

Recent Accounting Pronouncements

Reclassification

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	Dec. 31, 2013
Accounting Policies [Abstract]	'
Investments and Liabilities of the Companys Financial Assets	'
	The following table presents certain investments and liabilities of the Company’s financial assets measured and recorded at fair value on the Company’s condensed balance sheets on a recurring basis and their level within the fair value hierarchy as of December 31, 2013 and March 31, 2013:

	31-Dec-13

		Level 1		Level 2		Level 3		Total
	Fair value of Derivative Liability	$	-	$	908,378	$	-	$	908,378

	31-Mar-13

		Level 1		Level 2		Level 3		Total
	Fair value of Derivative Liability	$	-	$	398,603	$	-	$	398,603

CONVERTIBLE_NOTES_PAYABLE_Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	9 Months Ended
	Dec. 31, 2013
Convertible Note Payable [Abstract]	'
Convertible Notes Payable	'
	Convertible notes payable consist of the following as of December 31, 2013 and March 31, 2013:

		December 31,		March 31,
		2013		2013
	Subordinated unsecured convertible notes payable, interest at 6% per	$	625,000	$	625,000
	annum payable semi-annually (a)
	Convertible notes payable (b)		-		330,000
	Total convertible notes		625,000		955,000

	Less: note discount		-78,788		-374,592
	Convertible notes payable, net of note discount	$	546,212	$	580,408

	(a) On February 7, 2012, the Company entered into a Subscription Agreement (the “Subscription Agreement”) with one investor in a private placement, pursuant to which such investor purchased an aggregate of (i) 625,000 shares of common stock at a purchase price of $1.00 per share and (ii) convertible debentures with an aggregate principal amount of $ 625,000 convertible into a total of 693,774 shares of our common stock at prices ranging from $0.65 to $1.25, in five tranches over a 12 month period beginning on March 1, 2012, for proceeds to us of $ 250,000 per tranche. The conversion price of the common stock underlying each of the convertible debentures is subject to adjustment upon a reclassification or other change in the Company’s outstanding common stock and certain distributions to all holders of the Company’s common stock. The entire principal balance of each debenture is due and payable three years following its date of issuance unless earlier redeemed by the Company in accordance with its terms. Each of these convertible debentures bears interest at the rate of 6.0 % per annum, payable semi-annually in arrears on June 30 and December 31 of each year. During the nine months ended December 31, 2013, the aggregate accrued interest due on these convertible debentures of $37,500 was converted into 41,632 shares of the Company’s common stock based on the conversion rates of the five tranches of these convertible debentures ranging from $0.65 to $1.25 per share. As of December 31, 2013, all $625,000 of these convertible debentures were outstanding. If the outstanding principal on all of the convertible debentures issued pursuant to the Subscription Agreement were converted into common shares, as of December 31, 2013, the holders thereof would receive 693,773 shares of common stock.

	Upon the issuance of the convertible notes under the Subscription Agreement, the market price of our common shares was in excess of the conversion price, creating a beneficial conversion feature of $177,404 upon issuance, representing the amount by which the value of the shares into which the notes are convertible exceeded the aggregate conversion price on the date of issuance. The beneficial conversion feature was recorded as a discount to the notes payable and is being amortized over the life of the notes, the balance of which was $113,341 at March 31, 2013. During the nine months ended December 31, 2013, the Company recognized interest expense of $34,553 relating to the amortization of this discount, resulting in an unamortized balance of $78,788 as of December 31, 2013.

	(b) On October 29, 2012, we entered into a Securities Purchase Agreement with two investors providing for the issuance and sale of an aggregate of $500,000 in convertible debentures and warrants to purchase 1,000,000 shares of our common stock, for proceeds to us of $500,000. The financing closed on November 1, 2012. After deducting for fees and expenses, the aggregate net proceeds from the sale of the debentures and warrants was $445,000. During the year ended March 31, 2013, $170,000 of these debentures were converted into shares of the Company’s common stock leaving a balance due on these debentures at March 31, 2013 of $330,000. During the nine months ended December 31, 2013, the remaining debentures, totaling $330,000, were converted into 733,334 shares of common stock. As of December 31, 2013, there was no remaining balance due on these debentures and they have been cancelled in full.

	Each of the investors was also issued a warrant to purchase up to a number of shares of the Company’s common stock equal to 100% of the shares initially issuable to such investor upon conversion of the convertible debentures issued pursuant to the Securities Purchase Agreement, totaling up to 1,000,000 shares of common stock. The warrants had an initial exercise price of $0.70 per share, are exercisable immediately upon issuance and have a term of exercise equal to five years. The Company also issued warrants to purchase up to 80,000 shares of the Company’s common stock to its placement agent related to the financing that had an initial exercise price of $0.625 per share. On March 6, 2013, the exercise price of all the warrants was reduced to $0.50. On June 28, 2013, the exercise price of all of the warrants issued in the October 2012 financing was further reduced to $0.34.

	Each of the warrants includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants issued with the convertible debentures, provided that the exercise price shall not be reduced to less than $0.20 per share. The Company considered the current FASB guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” and determined that the exercise price of the warrants is not a fixed amount because it is subject to fluctuation based on the occurrence of future offerings or events. As a result, the Company determined that the warrants are not considered indexed to the Company’s own stock and characterized the initial fair value of these warrants as a derivative liability upon issuance. The Company determined the aggregate initial fair value of the warrants issued to investors and placement agent to be $523,458 upon issuance. These amounts were determined by management using a using a probability weighted average Black-Scholes Merton option pricing model.

	The total cost to the Company of the transactions related to the Securities Purchase Agreement was $578,458, which includes placement fees and expenses of $55,000 and the fair value of the warrant derivative of $523,458. To account for the these costs, the Company recorded a valuation discount of $500,000 upon issuance, and the incremental cost of $78,458 over the face amount of the convertible debentures was recorded as a financing cost during the year ended March 31, 2013. The Company was amortizing the valuation discount to interest expense over the life of the convertible debentures. During the nine months ended December 31, 2013, the Company recognized interest expense of $261,251 relating to the amortization of this discount, resulting in an unamortized balance of $0 as of December 31, 2013.

DERIVATIVE_LIABILITY_Tables

DERIVATIVE LIABILITY (Tables)	9 Months Ended
DERIVATIVE LIABILITY (Tables)	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Warrants	'
	At December 31, 2013, and as of March 31, 2013, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions:

	Warrants:

		December 31,			At Date of			March 31,
		2013			Issuance			2013
	Exercise Price	$	0.34-0.425		$	0.40 - $0.60		$	0.5
	Stock Price	$	0.42		$	0.35		$	0.45

	Risk-free interest rate		.02-1.295	%		2.52	%		0.25	%
	Expected volatility		46.94	%		78.7	%		123.68	%
	Expected life (in years)		0.25-4.5 years			0.50 - 5.0 years			4.5 years
	Expected dividend yield		0			0			0
	Fair Value:	$	908,378		$	1,249,025		$	398,603

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	9 Months Ended
STOCK OPTIONS (Tables)	Dec. 31, 2013
Stock Options [Abstract]	'
Options to Purchase Common Shares	'
	A summary of the Company’s stock option activity under the 2012 Stock Incentive Plan for the period ended December 31, 2013 is presented below:

		Shares	Weighted
			Average
			Exercise
			Price
	Balance at March 31, 2013	2,275,000	$	0.16
	Granted	3,500,000		0.39
	Exercised	-700,000		0.31
	Cancelled	-100,000		0.42
	Balance outstanding at December 31, 2013	4,975,000	$	0.27
	Balance exercisable at December 31, 2013	3,620,833	$	0.26

Stock Option Activity	'
	At December 31, 2013, options to purchase common shares were outstanding as follows:

		Number of	Weighted		Weighted
		options	Average		Average
			Exercise		Grant-date Stock
			Price		Price

	Options Outstanding, December 31, 2013	1,650,000	$	0.1	$	1
		200,000	$	0.27	$	0.27
		1,000,000	$	0.32	$	0.32
		300,000	$	0.35	$	0.35
		100,000	$	0.36	$	0.36
		1,600,000	$	0.4	$	0.4
		25,000	$	0.42	$	0.42
		100,000	$	0.44	$	0.44

		4,975,000

	Exercisable, December 31, 2013	1,362,500	$	0.1	$	1
		83,333	$	0.27	$	0.27
		500,000	$	0.32	$	0.32
		75,000	$	0.35	$	0.35
		1,600,000	$	0.4	$	0.4
		3,620,833

WARRANTS_Tables

WARRANTS (Tables)	9 Months Ended
WARRANTS (Tables)	Dec. 31, 2013
Warrants [Abstract]	'
Warrants	'
	At December 31, 2013, warrants to purchase common shares were outstanding as follows:

		Shares	Weighted
			Average
			Exercise
			Price
	Balance at March 31, 2013	1,080,000	$	0.5
	Granted	11,323,601		0.5
	Exercised	-4,676,472		0.41
	Cancelled	-	$	-
	Balance outstanding at December 31, 2013	7,727,129	$	0.41
	Balance exercisable at December 31, 2013	7,727,129

BUSINESS_AND_BASIS_OF_OPERATIO1

BUSINESS AND BASIS OF OPERATIONS (Details) (USD $)	Dec. 31, 2013
Nature And Continuance Of Operation [Line Items]	'
Accumulated deficit	$6,900,059

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Fair value of Derivative Liability (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Fair value of Derivative Liability	$908,378	$398,603
Fair Value, Inputs, Level 1 [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Fair value of Derivative Liability	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Fair value of Derivative Liability	908,378	398,603
Fair Value, Inputs, Level 3 [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Fair value of Derivative Liability	$0	$0

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended		9 Months Ended		78 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Stock Options To Purchase	4,975,000	'	4,975,000	'	4,975,000
Common Shares Issuable Under Convertible Note	693,773	'	693,773	'	693,773
General and Administrative	$796,017	$499,275	$2,120,541	$1,475,111	$5,169,759
Research and Development Expense	219,436	132,888	545,821	329,728	1,282,241
Restatement Adjustment [Member]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
General and Administrative	'	91,231	'	198,981	'
Research and Development Expense	$91,231	'	$198,981	'	'
Warrant [Member]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	'	7,727,129	'	'

CONVERTIBLE_NOTES_PAYABLE_Sche

CONVERTIBLE NOTES PAYABLE: Schedule of convertible notes payable (Details) (USD $)	Dec. 31, 2013		Mar. 31, 2013		Mar. 31, 2012
Extinguishment of Debt [Line Items]	'		'		'
Total convertible notes	$625,000		$955,000		'
Less: note discount	-78,788		-374,592		-113,341
Convertible Notes Payable [Member]	'		'		'
Extinguishment of Debt [Line Items]	'		'		'
Subordinated unsecured convertible notes payable, interest at 6% perannum payable semi-annually	625,000	[1]	625,000	[1]	'
Convertible notes payable	0	[2]	330,000	[2]	'
Total convertible notes	625,000		955,000		'
Less: note discount	-78,788		-374,592		'
Convertible notes payable, net of note discount	$546,212		$580,408		'

[1]	On February 7, 2012, the Company entered into a Subscription Agreement (the bSubscription Agreementb) with one investor in a private placement, pursuant to which such investor purchased an aggregate of (i) 625,000 shares of common stock at a purchase price of $1.00 per share and (ii) convertible debentures with an aggregate principal amount of $ 625,000 convertible into a total of 693,774 shares of our common stock at prices ranging from $0.65 to $1.25, in five tranches over a 12 month period beginning on March 1, 2012, for proceeds to us of $ 250,000 per tranche. The conversion price of the common stock underlying each of the convertible debentures is subject to adjustment upon a reclassification or other change in the Companybs outstanding common stock and certain distributions to all holders of the Companybs common stock. The entire principal balance of each debenture is due and payable three years following its date of issuance unless earlier redeemed by the Company in accordance with its terms. Each of these convertible debentures bears interest at the rate of 6.0 % per annum, payable semi-annually in arrears on June 30 and December 31 of each year. During the nine months ended December 31, 2013, the aggregate accrued interest due on these convertible debentures of $37,500 was converted into 41,632 shares of the Companybs common stock based on the conversion rates of the five tranches of these convertible debentures ranging from $0.65 to $1.25 per share. As of December 31, 2013, all $625,000 of these convertible debentures were outstanding. If the outstanding principal on all of the convertible debentures issued pursuant to the Subscription Agreement were converted into common shares, as of December 31, 2013, the holders thereof would receive 693,773 shares of common stock. Upon the issuance of the convertible notes under the Subscription Agreement, the market price of our common shares was in excess of the conversion price, creating a beneficial conversion feature of $177,404 upon issuance, representing the amount by which the value of the shares into which the notes are convertible exceeded the aggregate conversion price on the date of issuance. The beneficial conversion feature was recorded as a discount to the notes payable and is being amortized over the life of the notes, the balance of which was $113,341 at March 31, 2013. During the nine months ended December 31, 2013, the Company recognized interest expense of $34,553 relating to the amortization of this discount, resulting in an unamortized balance of $78,788 as of December 31, 2013.
[2]	On October 29, 2012, we entered into a Securities Purchase Agreement with two investors providing for the issuance and sale of an aggregate of $500,000 in convertible debentures and warrants to purchase 1,000,000 shares of our common stock, for proceeds to us of $500,000. The financing closed on November 1, 2012. After deducting for fees and expenses, the aggregate net proceeds from the sale of the debentures and warrants was $445,000. During the year ended March 31, 2013, $170,000 of these debentures were converted into shares of the Companybs common stock leaving a balance due on these debentures at March 31, 2013 of $330,000. During the nine months ended December 31, 2013, the remaining debentures, totaling $330,000, were converted into 733,334 shares of common stock. As of December 31, 2013, there was no remaining balance due on these debentures and they have been cancelled in full. Each of the investors was also issued a warrant to purchase up to a number of shares of the Companybs common stock equal to 100% of the shares initially issuable to such investor upon conversion of the convertible debentures issued under pursuant to the Securities Purchase Agreement, totaling up to 1,000,000 shares of common stock. The warrants had an initial exercise price of $0.70 per share, are exercisable immediately upon issuance and have a term of exercise equal to five years. The Company also issued warrants to purchase up to 80,000 shares of the Companybs common stock to its placement agent related to the financing that had an initial exercise price of $0.625 per share. On March 6, 2013, the exercise price of all the warrants was reduced to $0.50. On June 28, 2013, the exercise price of all of the warrants issued in the October 2012 financing was further reduced to $0.34. Each of the warrants includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Companybs common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants issued with the convertible debentures, provided that the exercise price shall not be reduced to less than $0.20 per share. The Company considered the current FASB guidance of bDetermining Whether an Instrument Indexed to an Entitybs Own Stockb and determined that the exercise price of the warrants is not a fixed amount because it is subject to fluctuation based on the occurrence of future offerings or events. As a result, the Company determined that the warrants are not considered indexed to the Companybs own stock and characterized the initial fair value of these warrants as a derivative liability upon issuance. The Company determined the aggregate initial fair value of the warrants issued to investors and placement agent to be $523,458 upon issuance. These amounts were determined by management using a using a probability weighted average Black-Scholes Merton option pricing model. The total cost to the Company of the transactions related to the Securities Purchase Agreement was $578,458, which includes placement fees and expenses of $55,000 and the fair value of the warrant derivative of $523,458. To account for the these costs, the Company recorded a valuation discount of $500,000 upon issuance, and the incremental cost of $78,458 over the face amount of the convertible debentures was recorded as a financing cost during the year ended March 31, 2013. The Company was amortizing the valuation discount to interest expense over the life of the convertible debentures. During the nine months ended December 31, 2013, the Company recognized interest expense of $261,251 relating to the amortization of this discount, and an unamortized balance of $0 as of December 31, 2013.

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Details) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

78 Months Ended

Oct. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Mar. 31, 2012

Dec. 31, 2013

Feb. 07, 2012

Extinguishment of Debt [Line Items]

Common stock share amount

625,000

Convertible debenture amount

$625,000

Debenture pursuant to Subscription Agreement

693,774

Receivable Common Shares

693,773

Debt Instrument, Unamortized Discount

78,788

374,592

113,341

78,788

Interest Expense, Debt

34,553

Fair value of beneficial conversion feature of convertible notes

177,404

Proceeds From Issuance Of Common Stock

500,000

1,133,250

Conversion of notes payable and accrued interest to common stock

1,249,025

Financing cost

78,458

Loan Placement Fees

55,000

Derivative, Fair Value, Net

523,458

Warrants To Purchase Of Common Stock

1,000,000

Free Standing Derivative Value

500,000

Proceeds from Issuance or Sale of Equity

445,000

1,133,250

425,000

1,783,250

Warrants Exercise Price

$0.42

$0.34

Conversion of Stock, Shares Issued

733,334

Debenture Outstanding Amount

330,000

Warrants Granted In Period

1,000,000

11,323,601

Warrants Granted Period In Weighted Exercise Price

0.7

0.42

0.5

Minimum Warrants Exercise Price

$0.20

Debt Conversion, Original Debt, Amount

170,000

Payment Of Costs Related To Purchase Agreement

578,458

Placement Agent Agreement [Member]

Extinguishment of Debt [Line Items]

Warrants Granted In Period

80,000

294,185

Warrants Granted Period In Weighted Exercise Price

0.425

Placement Agent Agreement [Member] | Dawson [Member]

Extinguishment of Debt [Line Items]

Warrants Granted In Period

80,000

Warrants Granted Period In Weighted Exercise Price

0.625

0.5

Private Placement [Member]

Extinguishment of Debt [Line Items]

Sale of Stock, Price Per Share

Warrant [Member]

Extinguishment of Debt [Line Items]

Debt Instrument, Unamortized Discount

Interest Expense, Debt

261,251

Derivative, Fair Value, Net

523,458

Conversion Shares Issuable To Purchaser Percentage

100.00%

Warrants Exercise Price

$0.70

Subordinated Unsecured Convertible Notes Payable Interest At Six Percent Per Annum Payable Quarterly [Member]

Extinguishment of Debt [Line Items]

Conversion of notes payable and accrued interest to common stock

37,500

Subordinated Unsecured Convertible Notes Payable Interest At Six Percent Per Annum Payable Semi Annually [Member]

Extinguishment of Debt [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

6.00%

Conversion of notes payable and accrued interest to common stock

41,632

Convertible Notes Payable [Member]

Extinguishment of Debt [Line Items]

Debt Instrument, Unamortized Discount

78,788

374,592

78,788

Convertible Subordinated Debt

625,000

[1]

625,000

[1]

625,000

[1]

625,000

[1]

Convertible Debt

[2]

330,000

[2]

Minimum [Member]

Extinguishment of Debt [Line Items]

Debenture conversion price

$0.65

Minimum [Member] | Subordinated Unsecured Convertible Notes Payable Interest At Six Percent Per Annum Payable Semi Annually [Member]

Extinguishment of Debt [Line Items]

Debt Instrument, Convertible, Conversion Price

$0.65

Maximum [Member]

Extinguishment of Debt [Line Items]

Debenture conversion price

$1.25

Maximum [Member] | Subordinated Unsecured Convertible Notes Payable Interest At Six Percent Per Annum Payable Semi Annually [Member]

Extinguishment of Debt [Line Items]

Debt Instrument, Convertible, Conversion Price

$1.25

Per Tranche [Member]

Extinguishment of Debt [Line Items]

Convertible debenture amount

$250,000

[1]

On February 7, 2012, the Company entered into a Subscription Agreement (the bSubscription Agreementb) with one investor in a private placement, pursuant to which such investor purchased an aggregate of (i) 625,000 shares of common stock at a purchase price of $1.00 per share and (ii) convertible debentures with an aggregate principal amount of $ 625,000 convertible into a total of 693,774 shares of our common stock at prices ranging from $0.65 to $1.25, in five tranches over a 12 month period beginning on March 1, 2012, for proceeds to us of $ 250,000 per tranche. The conversion price of the common stock underlying each of the convertible debentures is subject to adjustment upon a reclassification or other change in the Companybs outstanding common stock and certain distributions to all holders of the Companybs common stock. The entire principal balance of each debenture is due and payable three years following its date of issuance unless earlier redeemed by the Company in accordance with its terms. Each of these convertible debentures bears interest at the rate of 6.0 % per annum, payable semi-annually in arrears on June 30 and December 31 of each year. During the nine months ended December 31, 2013, the aggregate accrued interest due on these convertible debentures of $37,500 was converted into 41,632 shares of the Companybs common stock based on the conversion rates of the five tranches of these convertible debentures ranging from $0.65 to $1.25 per share. As of December 31, 2013, all $625,000 of these convertible debentures were outstanding. If the outstanding principal on all of the convertible debentures issued pursuant to the Subscription Agreement were converted into common shares, as of December 31, 2013, the holders thereof would receive 693,773 shares of common stock. Upon the issuance of the convertible notes under the Subscription Agreement, the market price of our common shares was in excess of the conversion price, creating a beneficial conversion feature of $177,404 upon issuance, representing the amount by which the value of the shares into which the notes are convertible exceeded the aggregate conversion price on the date of issuance. The beneficial conversion feature was recorded as a discount to the notes payable and is being amortized over the life of the notes, the balance of which was $113,341 at March 31, 2013. During the nine months ended December 31, 2013, the Company recognized interest expense of $34,553 relating to the amortization of this discount, resulting in an unamortized balance of $78,788 as of December 31, 2013.

[2]

On October 29, 2012, we entered into a Securities Purchase Agreement with two investors providing for the issuance and sale of an aggregate of $500,000 in convertible debentures and warrants to purchase 1,000,000 shares of our common stock, for proceeds to us of $500,000. The financing closed on November 1, 2012. After deducting for fees and expenses, the aggregate net proceeds from the sale of the debentures and warrants was $445,000. During the year ended March 31, 2013, $170,000 of these debentures were converted into shares of the Companybs common stock leaving a balance due on these debentures at March 31, 2013 of $330,000. During the nine months ended December 31, 2013, the remaining debentures, totaling $330,000, were converted into 733,334 shares of common stock. As of December 31, 2013, there was no remaining balance due on these debentures and they have been cancelled in full. Each of the investors was also issued a warrant to purchase up to a number of shares of the Companybs common stock equal to 100% of the shares initially issuable to such investor upon conversion of the convertible debentures issued under pursuant to the Securities Purchase Agreement, totaling up to 1,000,000 shares of common stock. The warrants had an initial exercise price of $0.70 per share, are exercisable immediately upon issuance and have a term of exercise equal to five years. The Company also issued warrants to purchase up to 80,000 shares of the Companybs common stock to its placement agent related to the financing that had an initial exercise price of $0.625 per share. On March 6, 2013, the exercise price of all the warrants was reduced to $0.50. On June 28, 2013, the exercise price of all of the warrants issued in the October 2012 financing was further reduced to $0.34. Each of the warrants includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Companybs common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants issued with the convertible debentures, provided that the exercise price shall not be reduced to less than $0.20 per share. The Company considered the current FASB guidance of bDetermining Whether an Instrument Indexed to an Entitybs Own Stockb and determined that the exercise price of the warrants is not a fixed amount because it is subject to fluctuation based on the occurrence of future offerings or events. As a result, the Company determined that the warrants are not considered indexed to the Companybs own stock and characterized the initial fair value of these warrants as a derivative liability upon issuance. The Company determined the aggregate initial fair value of the warrants issued to investors and placement agent to be $523,458 upon issuance. These amounts were determined by management using a using a probability weighted average Black-Scholes Merton option pricing model. The total cost to the Company of the transactions related to the Securities Purchase Agreement was $578,458, which includes placement fees and expenses of $55,000 and the fair value of the warrant derivative of $523,458. To account for the these costs, the Company recorded a valuation discount of $500,000 upon issuance, and the incremental cost of $78,458 over the face amount of the convertible debentures was recorded as a financing cost during the year ended March 31, 2013. The Company was amortizing the valuation discount to interest expense over the life of the convertible debentures. During the nine months ended December 31, 2013, the Company recognized interest expense of $261,251 relating to the amortization of this discount, and an unamortized balance of $0 as of December 31, 2013.

DERIVATIVE_LIABILITY_weighted_

DERIVATIVE LIABILITY: weighted average pricing model (Details) (USD $)	9 Months Ended	12 Months Ended
	Dec. 31, 2013	Mar. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Exercise Price	'	$0.50
Stock Price	$0.42	$0.45
Risk-free interest rate	'	0.25%
Expected volatility	46.94%	123.68%
Expected life (in years)	'	'4 years 6 months
Expected dividend yield	0.00%	0.00%
Fair value of Derivative Liability	$908,378	$398,603
At Date of Issuance [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Stock Price	'	$0.35
Risk-free interest rate	'	2.52%
Expected volatility	'	78.70%
Expected dividend yield	'	0.00%
Fair value of Derivative Liability	$1,249,025	$1,249,025
Maximum [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Exercise Price	$0.43	'
Risk-free interest rate	1.30%	'
Expected life (in years)	'4 years 6 months	'
Maximum [Member] \| At Date of Issuance [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Exercise Price	'	$0.60
Expected life (in years)	'	'5 years
Minimum [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Exercise Price	$0.34	'
Risk-free interest rate	0.02%	'
Expected life (in years)	'3 months	'
Minimum [Member] \| At Date of Issuance [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Exercise Price	'	$0.40
Expected life (in years)	'	'6 months

DERIVATIVE_LIABILITY_Details

DERIVATIVE LIABILITY (Details) (USD $)	3 Months Ended		9 Months Ended		78 Months Ended
DERIVATIVE LIABILITY (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Mar. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'
Fair value of Derivative Liability	$908,378	'	$908,378	'	$908,378	$398,603
Change in fair value of derivative liability	275,232	234,321	553,343	234,321	678,197	'
Extinguishment Of Warrant Derivative Liabilities	'	'	185,907	0	185,907	'
At Date of Issuance [Member]	'	'	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'	'
Fair value of Derivative Liability	$1,249,025	'	$1,249,025	'	$1,249,025	$1,249,025

EQUITY_Details

EQUITY (Details) (USD $)	1 Months Ended		3 Months Ended	9 Months Ended		12 Months Ended	78 Months Ended
	Dec. 31, 2013	Oct. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2013	Dec. 31, 2013
	Dec. 31, 2013	Oct. 31, 2012	Dec. 31, 2013	Warrant	Dec. 31, 2012	Mar. 31, 2013	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Warrants Granted In Period	'	1,000,000	'	11,323,601	'	'	'
Payments of Financing Costs, Total	'	'	'	$116,750	'	'	'
Shares sold	'	500,000	'	1,133,250	'	'	'
Warrants Granted Period In Weighted Exercise Price	'	0.7	0.42	0.5	'	0.5	'
Stock Issued During Period, Value, Share-based Compensation, Gross	'	'	'	80,604	'	'	'
Conversion of notes payable and accrued interest to common stock	'	'	'	1,249,025	0	'	1,249,025
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants	'	'	'	-115,775	'	'	'
Number of Common Stock To Be Issued Upon Exercise of Warrants	3,362,472	'	'	11,029,416	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value	'	'	'	760,000	'	'	'
Minimum Warrants Exercise Price	'	'	'	$0.20	'	'	'
Common Stock [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants	'	'	'	3,676	'	'	'
Stock and Warrants Issued During Period, Share, Preferred Stock and Warrants	'	'	'	3,676,472	'	'	'
Number of Common Stock To Be Issued Upon Exercise of Warrants	'	'	'	11,029,416	'	'	'
Warrant [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Stock and Warrants Issued During Period, Share, Preferred Stock and Warrants	'	'	'	3,676,472	'	'	'
Number of Common Stock To Be Issued Upon Exercise of Warrants	'	'	'	11,029,416	'	'	'
Warrant One [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Warrants Granted Period In Weighted Exercise Price	'	'	'	0.4	'	'	'
Warrant Two [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Warrants Granted Period In Weighted Exercise Price	'	'	'	0.5	'	'	'
Warrant Three [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Warrants Granted Period In Weighted Exercise Price	'	'	'	0.6	'	'	'
Placement Agent Agreement [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Warrants Granted In Period	'	'	'	294,185	'	'	'
Warrants Granted Period In Weighted Exercise Price	'	'	'	0.425	'	'	'
Unvested Issued Common Stock [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Unvested Issued Common Stock	76,896	'	76,896	76,896	'	'	76,896
Stock Incentive Plan 2012 [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value	'	'	'	189,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	'	100,000	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'31 months	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	'	'	'	6,968	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	28,029	'	28,029	28,029	'	'	28,029
Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value	'	'	'	$36,000	'	'	'
employees and a director [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	700,000	'	'	'
Subscription Agreement [Member]	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Stock Issued During Period, Shares, Conversion of Convertible Securities	'	'	'	1,250,000	'	'	'
Stock Issued During Period Shares Conversion Of Convertible Securities Per Share	'	'	'	$0.34	'	'	'

STOCK_OPTIONS_Purchase_common_

STOCK OPTIONS: Purchase common shares (Details) (USD $)	9 Months Ended
STOCK OPTIONS: Purchase common shares (Details) (USD $)	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares, Balance	2,275,000
Shares, Granted	3,500,000
Shares, Exercised	-700,000
Shares, Cancelled	-100,000
Shares, Balance	4,975,000
Shares, Ending exercisable	3,620,833
Weighted Average Exercise Price, Balance	$0.16
Weighted Average Exercise Price, Granted	$0.39
Weighted Average Exercise Price, Exercised	$0.31
Weighted Average Exercise Price, Cancelled	$0.42
Weighted Average Exercise Price, Balance	$0.27
Weighted Average Exercise Price, exercisable	$0.26

STOCK_OPTIONS_Stock_option_act

STOCK OPTIONS: Stock option activity (Details) (USD $)

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Stock Options 1 [Member]

Stock Options 2 [Member]

Stock Options 3 [Member]

Stock Option 4 [Member]

Stock Option 5 [Member]

Stock Options 6 [Member]

Stock Options 7 [Member]

Stock Options 8 [Member]

Vested 1 [Member]

Vested 2 [Member]

Vested 3 [Member]

Vested 4 [Member]

Vested 5 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options Outstanding

4,975,000

2,275,000

1,650,000

200,000

1,000,000

300,000

100,000

1,600,000

25,000

100,000

Weighted Average Exercise Price, Options Outstanding

$0.27

$0.16

$0.10

$0.27

$0.32

$0.35

$0.36

$0.40

$0.42

$0.44

$0.10

$0.27

$0.32

$0.35

$0.40

Weighted Average Grant-Date Stock Price, Options Outstanding

$0.27

$0.32

$0.35

$0.36

$0.40

$0.42

$0.44

Options vested

1,362,500

83,333

500,000

75,000

1,600,000

Weighted Average Grant-Date Stock Price, Vested

$0.27

$0.32

$0.35

$0.40

Shares, Ending exercisable

3,620,833

STOCK_OPTIONS_Details

STOCK OPTIONS (Details) (USD $)	9 Months Ended
STOCK OPTIONS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share based Compensation Arrangement By Share based Payment Award Grants Expected Term	'5 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$868,497	$708,376
Unamortized cost of outstanding stock-based awards	136,189	'
Weighted Average Remaining Vesting Period	'2 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	755,000	'
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value	760,000	'
Vested One [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	100,000	'
Vested Two [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	400,000	'
Vested Three [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	2,000,000	'
Vested Four [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	1,000,000	'
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Volatility, Options Outstanding	46.94%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions	0.25%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'3 years	'
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Volatility, Options Outstanding	78.70%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions	0.63%	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'10 years	'
Consultants One [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	500,000	'
Consultants Two [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	3,000,000	'
Stock Incentive Plan 2012 [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value	$189,000	'

WARRANTS_Warrants_to_purchase_

WARRANTS: Warrants to purchase common shares (Details) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Oct. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Mar. 31, 2013
Class of Warrant or Right [Line Items]	'	'	'	'
Shares, Balance	'	'	1,080,000	'
Shares, Granted	1,000,000	'	11,323,601	'
Shares, Exercised	'	'	-4,676,472	'
Shares, Cancelled	'	'	0	'
Shares, Balance	'	7,727,129	7,727,129	1,080,000
Shares, exercisable	'	7,727,129	7,727,129	'
Weighted Average Exercise Price, Balance	'	'	0.5	'
Weighted Average Exercise Price, Granted	0.7	0.42	0.5	0.5
Weighted Average Exercise Price, Exercised	'	'	$0.41	'
Weighted Average Exercise Price, Cancelled	'	'	$0	'
Weighted Average Exercise Price Balance	'	0.41	0.41	0.5

WARRANTS_Details

WARRANTS (Details) (USD $)

1 Months Ended

2 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

78 Months Ended

6 Months Ended

9 Months Ended

6 Months Ended

9 Months Ended

6 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

Dec. 31, 2013

Oct. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Dec. 31, 2013

Oct. 31, 2012

Dec. 31, 2013

Mar. 31, 2013

Warrant

Warrant One [Member]

Warrant Two [Member]

Warrant Three [Member]

Warrant [Member]

Placement Agent Agreement [Member]

Warrant

Dawson [Member]

Class of Warrant or Right [Line Items]

Shares, Granted

1,000,000

11,323,601

3,676,472

80,000

294,185

80,000

Warrants Granted Period In Weighted Exercise Price

0.7

0.42

0.5

0.4

0.5

0.6

0.425

0.625

0.5

Warrants Exercise Price

$0.42

$0.34

$0.70

Number of Common Stock To Be Issued Upon Exercise of Warrants

3,362,472

11,029,416

Minimum Warrants Exercise Price

$0.20

Warrants Exercised

3,362,472

314,000

1,000,000

Cost To Induce Exercise Of Warrants

$173,824

Warrants Outstanding Intrinsic Value

78,459

Proceeds from Warrant Exercises

$1,327,504

$157,000

$340,000

$1,824,505

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]	'
Net operating loss carry forwards	$6,900,059

RELATED_PARTY_TRANSACTIONS_AND1

RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS (Details) (USD $)

1 Months Ended

9 Months Ended

Sep. 30, 2011

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2012

Aug. 20, 2012

Jan. 31, 2012

Sep. 01, 2011

Dec. 31, 2013

Apr. 23, 2012

Dec. 31, 2013

Mar. 31, 2012

Aug. 22, 2012

Jan. 31, 2012

Sutter Buttes Llc [Member]

Sutter Lease [Member]

Carlson Lease [Member]

Sacramento Lease [Member]

Office and Laboratory [Member]

acre

Operating Leased Assets [Line Items]

Lease agreement, increased rent, per month

$1,500

$1,000

$500

Land lease agreement, aggregate rent amount

115,250

107,600

1,000

Payments for Rent

250,000

Area of Land

1,000

Operating Leases, Rent Expense

93,750

Due from Related Parties

41,664

Security deposit

2,500

1,500

1,000

Monthly Payments For Rent

$2,300

Lease Agreement Expiry Term

'5 years

'24 months

Lease Agreement Expiry Date

1-Sep-16

COMMITMENTS_Details

COMMITMENTS (Details) (USD $)	9 Months Ended
COMMITMENTS (Details) (USD $)	Dec. 31, 2013
Commitments And Contingencies [Line Items]	'
Initial Term Of Patents License Agreement	'10 years
Cash Fees And Payable For Patents License Agreement	$50,000
Percentage Of Royalties On Sale Price Of Products	0.50%
Minimum Annual Royalty	10,000
Cash Due Of Patents License Agreement Due In One Year	12,500
Proceeds From Patent Prosecution Cost	$50,000

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	9 Months Ended		78 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Feb. 07, 2012	Feb. 28, 2014	Jan. 31, 2014
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Feb. 07, 2012	Subsequent Event [Member]	Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	'	'	'	'	150,000
Investment Options, Exercise Price	'	'	'	'	'	$0.10
Proceeds From Stock Options Exercised	$76,000	$35,000	$289,000	'	'	$15,000
Convertible Debenture Total	'	'	'	625,000	625,000	'
Conversion Of Convertible Debentures and Accrued Interest into Common Stock, Value	$1,249,025	$0	$1,249,025	'	$1,562.50	'
Conversion Of Convertible Debentures and Accrued Interest into Common Stock, Shares	'	'	'	'	695,511	'